DELIRIUM and Naproxen


DELIRIUM Symptoms and Causes

Delirium is a condition that features rapidly changing mental states. It causes confusion and changes in behavior. Besides falling in and out of consciousness, there may be problems with

  • Attention and awareness
  • Thinking and memory
  • Emotion
  • Muscle control
  • Sleeping and waking

Causes of Delirium include medications, poisoning, serious illnesses or infections, and severe pain. It can also be part of some mental illnesses or dementia.

Delirium and dementia have similar symptoms, so it can be hard to tell them apart. They can also occur together. Delirium starts suddenly and can cause hallucinations. The symptoms may get better or worse, and can last for hours or weeks. On the other hand, dementia develops slowly and does not cause hallucinations. The symptoms are stable, and may last for months or years.

Delirium tremens is a serious type of alcohol withdrawal syndrome. It usually happens to people who stop drinking after years of alcohol abuse.

People with Delirium often, though not always, make a full recovery after their underlying illness is treated.

Check out the latest treatments for DELIRIUM

DELIRIUM treatment research studies

Naproxen clinical trials, surveys and public health registries

Find Drug Side Effect reports

Naproxen Side Effects

Nausea (230)
Gastrointestinal Haemorrhage (220)
Pain (205)
Renal Failure Acute (198)
Dyspnoea (188)
Haemoglobin Decreased (171)
Completed Suicide (169)
Vomiting (162)
Dizziness (158)
Diarrhoea (155)
Gastric Ulcer (153)
Abdominal Pain (149)
Haematemesis (145)
Gastric Haemorrhage (137)
Chest Pain (123)
Duodenal Ulcer (122)
Abdominal Pain Upper (118)
Pruritus (118)
Anaemia (109)
Arthralgia (104)
Asthenia (65)
Pulmonary Embolism (64)
Rash (63)
No Adverse Event (63)
Melaena (63)
Upper Gastrointestinal Haemorrhage (62)
Headache (62)
Malaise (61)
Oedema Peripheral (58)
Deep Vein Thrombosis (58)
Urticaria (57)
Hypersensitivity (56)
Toxicity To Various Agents (56)
Anxiety (55)
Pyrexia (53)
Fatigue (50)
Faeces Discoloured (50)
Back Pain (49)
Cardiac Arrest (49)
Pain In Extremity (47)
Cholelithiasis (46)
Hypotension (45)
Overdose (44)
Injury (44)
Swelling Face (43)
Gastritis (42)
Feeling Abnormal (42)
Angioedema (42)
Depression (41)
Blood Creatinine Increased (39)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

DELIRIUM Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Preventing ICU Subsyndromal DELIRIUM Conversion to DELIRIUM With Haloperidol
Condition: Subsyndromal DELIRIUM
Interventions: Drug: Haloperidol decanoate;   Drug: Placebo
Outcome Measures: Conversion from subsyndromal DELIRIUM to DELIRIUM during the period of study drug administration (up to 10 days).;   The number of hours spent agitated (SAS >/=5) as percent of time study drug administered (up to 10 days).;   Duration of mechanical ventilation.;   Clinically significant QTc interval prolongation (≥ 500 msec or an increase of more than 60msec above baseline);   Extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   The number of hours spent excessively sedated (SAS ≤ 2) as a percent of time study drug administered (up to 10 days).;   Cognition, incidence of anxiety, incidence of depressive symptoms, quality of life (ie., functional status and emotional well being)and sleep quality.
2 Recruiting Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative DELIRIUM in Elderly Patients
Condition: Postoperative DELIRIUM
Outcome Measures: Incidence of postoperative DELIRIUM;   Factor related to postoperative DELIRIUM;   Long-term outcomes (cognitive impairment)
3 Recruiting Efficacy of Quetiapine for Pediatric DELIRIUM
Condition: DELIRIUM
Interventions: Drug: quetiapine;   Other: Placebo
Outcome Measures: Time to first resolution of DELIRIUM;   Total ICU days with DELIRIUM
4 Recruiting Effects of Prophylactic Use of Haloperidol in Critically Ill Patients With a High Risk for DELIRIUM
Condition: DELIRIUM
Intervention: Drug: Haloperidol
Outcome Measures: All cause mortality;   DELIRIUM incidence during ICU stay;   Number of DELIRIUM free days;   DELIRIUM related outcome during ICU stay;   Determining efficacy in different risk groups;   Side effects of haloperidol prophylaxis during prophylactic treatment
5 Recruiting Prospective Randomised Controlled Trial of DELIRIUM Management by Geriatric Medicine Versus General Medicine
Condition: DELIRIUM
Intervention: Other: Geriatric assessment review
Outcome Measures: Return home rate;   Survival;   Percentage residing at home;   Hospital complications of DELIRIUM
6 Recruiting Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of DELIRIUM
Condition: DELIRIUM
Interventions: Drug: Quetiapine;   Drug: Haloperidol;   Drug: Placebo
Outcome Measures: Time to first resolution of DELIRIUM;   Days in DELIRIUM during the study;   Duration of DELIRIUM;   Severity of DELIRIUM (highest Nu-DESC score, mean episode Nu-DESC score);   ICU and hospital mortality;   ICU and hospital length of stay;   Length of mechanical ventilation;   Time spent deeply sedated (RASS <3);   Episodes of subject-initiated device removal;   Use of haloperidol therapy (including total dose in haloperidol equivalents during the study, number of doses, number of days of therapy, use of rescue IV haloperidol);   Average daily and maximum total antipsychotic drug dose in haloperidol equivalents;   Duration of study drug administration;   Use of benzodiazepines;   Use of opioids;   QTc prolongation;   Extrapyramidal symptoms;   Neuroleptic malignant syndrome
7 Unknown  Risperidone and Zotepine in the Treatment of DELIRIUM
Condition: DELIRIUM
Intervention: Drug: Risperidone and Zolpidem for DELIRIUM
Outcome Measures: DELIRIUM rating scale;   MMSE, CGI, side effect profile, HRV
8 Recruiting Prevention of DELIRIUM After Bone Marrow Transplantation
Condition: DELIRIUM
Interventions: Device: Bright light therapy;   Device: Sham light
Outcome Measures: Incidence of DELIRIUM (Time to the development of DELIRIUM based on meeting criteria on the DELIRIUM Rating Scale and/or Memorial DELIRIUM Assessment Scale);   Length and severity of DELIRIUM episodes;   Average dose of antipsychotic medications required to manage DELIRIUM;   Hospital length of stay;   Complications (falls, aspiration, infections, nutritional deficits)
9 Recruiting Pharmacological Management of DELIRIUM
Conditions: DELIRIUM;   Cognitive Impairment
Interventions: Behavioral: Reduced exposure to anticholinergics;   Procedure: Reduced exposure to benzodiazepines;   Drug: Haloperidol;   Procedure: Usual care
Outcome Measures: DELIRIUM severity, days free of DELIRIUM and coma, measured by DRS-R-98, CAM-ICU, and RASS;   Length of stay;   Mortality;   Hospital-acquired complications related to DELIRIUM or DELIRIUM management
10 Recruiting Early Nurse Detection and Management of DELIRIUM
Condition: DELIRIUM Superimposed on Dementia
Intervention: Behavioral: END-DSD
Outcome Measures: Severity of DELIRIUM;   Inappropriate CNS-Active Medication Use;   Nurse Detection of DELIRIUM;   DELIRIUM Duration
11 Unknown  Impact of Impaired Cerebral Autoregulation on Postoperative DELIRIUM in Elderly Patients Undergoing Spine Surgery
Condition: DELIRIUM
Outcome Measures: Incidence of post-operative DELIRIUM in elderly patients undergoing spine surgery at Johns Hopkins Hospital;   Severity of postoperative DELIRIUM, using DELIRIUM Rating Scale-Revised-1998, in elderly patients undergoing spine surgery.
12 Recruiting Anesthesia-analgesia Methods and Postoperative DELIRIUM
Conditions: DELIRIUM;   Postoperative Complications
Intervention: Other: Combined Epi-GA/PCEA
Outcome Measures: Incidence of postoperative DELIRIUM;   Incidence of postoperative complications;   30-day mortality;   VAS pain score;   Duration of hospital stay after surgery;   Daily prevalence of postoperative DELIRIUM
13 Recruiting Impact of a Multifaceted Program to Prevent Postoperative DELIRIUM in the Elderly
Condition: Postoperative DELIRIUM
Intervention: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program)
Outcome Measures: Postoperative DELIRIUM rate within 7 days after surgery;   Mean DELIRIUM intensity within 7 days after surgery;   Length of hospital stay;   Postoperative complications 30 days after surgery incidence;   Mortality 6 months after surgery;   Feasibility of the multidisciplinary prevention program
14 Recruiting Does Nightly Dexmedetomidine Improve Sleep and Reduce DELIRIUM in ICU Patients?
Conditions: Sleep Deprivation;   DELIRIUM
Interventions: Drug: Dexmedetomidine;   Other: Placebo
Outcome Measures: Development of DELIRIUM;   Development of subsyndromal DELIRIUM
15 Recruiting Instruments for DELIRIUM Assessment Regarding to Analgesia Sedation and Ventilator Status
Condition: DELIRIUM
Outcome Measures: Sensitivity of the DELIRIUM screening/diagnosing tool "Confusion Assessment Method for the ICU (CAM-ICU)" regarding sedation and ventilator status.;   Sensitivity of the DELIRIUM-screening tool "Intensive-Care DELIRIUM Screening Checklist(ICDSC)" regarding sedation and ventilator status.;   Sensitivity of the DELIRIUM screening tool "Nursing DELIRIUM Screening Scale (Nu-DESC)" regarding sedation and ventilator status.;   Specificity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding sedation and ventilator status.;   Calculation and Analysis of the positive predictive values of the assessed DELIRIUM-screening scales.;   Incidence of DELIRIUM;   Incidence of Subsyndromale DELIRIUM (SSD);   Analgesia;   Ventilator status;   Administered neuroleptics, cumulative;   Administered analgesics, cumulative;   Administered sedatives, cumulative;   Severity of illness;   Antibiotics/infections;   ICU length of stay;   Duration of mechanical ventilation;   Discharge mode;   28-day mortality;   Specificity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding analgesia.;   Sensitivity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding analgesia.
16 Recruiting Dexmedetomidine on Postoperative DELIRIUM and Quality of Recovery in Geriatric Patients
Condition: DELIRIUM, Postoperative
Interventions: Drug: Placebo;   Drug: Dexmedetomidine
Outcome Measures: Postoperative DELIRIUM;   Length of PACU stay;   hemodynamic parameters;   incidence of postoperative nausea and vomiting;   quality of recovery determined by QOR40 and Postoperative Quality Recovery Scale (PQRS);   Postoperative Stroke
17 Recruiting Prevention of DELIRIUM With Light in the Intensive Care Unit
Condition: DELIRIUM
Intervention: Other: Circadian light
Outcome Measures: Prevalence of DELIRIUM;   DELIRIUM prevalence;   Severity of DELIRIUM;   Duration of DELIRIUM;   Prevalence of subsyndromal DELIRIUM (SSD);   Severity of anxiety;   Cognitive Dysfunction;   Post-Traumatic Stress Disorder (PTSD);   Sleep quality;   ICU length of stay;   Duration of mechanical ventilation;   Hospital length of stay;   Level of sedation;   Pain level;   Amount of administered opioids;   Amount of administered benzodiazepines;   Amount of administered sedatives;   Amount of administered antipsychotics;   Mortality;   Light levels (lux) Light levels (lux);   Light frequencies;   Noise levels (decibel)
18 Unknown  Validating a DELIRIUM Prediction Model for Critically Ill Patients
Condition: DELIRIUM
Outcome Measures: DELIRIUM;   markers of inflammation
19 Recruiting Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op DELIRIUM
Condition: DELIRIUM
Outcome Measures: To evaluate whether rSO2 and/or CBF during CPB is lower in patients who experience DELIRIUM within three days after cardiac surgery compared with patients without DELIRIUM;   recovery pattern of rSO2
20 Recruiting 4-question "RACY" DELIRIUM Screening Tool Validation Study
Condition: DELIRIUM
Intervention: Other: RACY test
Outcome Measures: Diagnostic accuracy (Sensitivity, specificity, likelihood ratios) of the "RACY" DELIRIUM screening tool;   12-month cognitive outcomes in patients <50 years;   Measurement of IL-6, IL-2, TNF-alpha, IFN-gamma, IGF-1, MCP-1, and hsCRP